Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | Ahmed Ahmed, Nancy Zaarour and colleagues at the University of Oxford are developing ‘OvarianVax’, a vaccine to tackle late-stage diagnosis of ovarian cancer, with the intention to prevent it in the first place, initially in high-risk groups. The team will use ex vivo organoid models and donor blood cones to identify the target antigens and test the effectiveness of the vaccine. The study will be strongly informed by input from patients. OvarianVax is one of several projects funded under our prevention research strategy, which aims to find more precise ways to prevent cancer. |
| |
| |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | Applications accepted all year round |
|
---|
| | | | | | Applications accepted all year round |
|
---|
| | | | Applications accepted all year round |
|
---|
| | | | Applications accepted all year round |
|
---|
|
| |
|
|
C-Further: expression of interest deadline approaching |
| Do you have a novel therapeutic asset in the childhood cancer space? C-Further wants to hear from you. C-Further offers resource and a supportive pathway to advance novel therapeutic assets. If selected, you’ll gain access to cutting-edge facilities, funding, resources and expertise to develop your discovery into a therapeutic for children and young people affected by cancer. The expression of interest deadline is 1 November 2024. |
| |
|
|
|
| | Following the successful 2023 webinar series, we’re back with a new series dedicated to exploring children’s and young people’s cancers across the research pipeline. The webinar series, led by international experts, will begin on 25 November from 3–4:30pm (GMT) and will focus on exploring therapeutic discovery research. You'll hear from researchers working to translate their research to develop more effective, targeted treatments for children and young people affected by cancer. We'll also highlight opportunities to engage with the newly launched international consortium, C-Further. Stay updated on the latest news and upcoming webinars by following #ExploringCYPCancers on our socials. | |
| | | | Great Ormond Street Hospital Charity has committed to invest at least £15m over the next five years to transform the outcomes and experiences for children and young people affected by cancer. The strategy focuses on three key priorities: develop new, more effective targeted treatments and cures, improve the experience and quality of life of patients and translate research discoveries into the NHS. | |
|
---|
|
|
|
|
3rd year supporting researchers, fostering entrepreneurship and more: read the Cancer Research Horizons annual review |
| Our innovation arm, Cancer Research Horizons, has published its third annual review, reflecting on its achievements in driving progress to translate promising research into medicines, start-ups, treatments and diagnostics for patients. In the past year, they have helped over 150 scientists and teams take the next step on their journeys through entrepreneurial programmes, accelerator and incubator schemes, and training and mentorship opportunities. Learn more about how scientists are progressing their research as well as Cancer Research Horizons’ impact. |
| |
|
|
|
| | Benjamin Simons, Colinda Scheele, Jacco van Rheenen and colleagues have shown the existence of multiple layers of protection to stop mutated clones from spreading within the breast. They mapped out the fate of cells that acquire mutations in the mouse mammary epithelium to gain insights into the mechanisms that inhibit the mutant clone expansion. The Cancer Grand Challenges team PRECISION, funded by Cancer Research UK and the Dutch Cancer Society, found that there are three layers of protection. These act together to eliminate most cells that acquire somatic mutations at the expense of driving the accelerated expansion of a minority of cells, which can colonise large areas. The findings published in Nature identified the molecular mechanisms behind why having fewer menstrual cycles is associated with decreased breast cancer risk.
| |
| | | | In a recent publication in Science, Adrian Hayday and colleagues discussed the mechanisms of gamma delta (γδ) T cell immunotherapy and explored ongoing clinical applications. The review highlights the capability of γδ T cells to target a wide range of tumours with low mutagenic loads among patients of diverse ethnicities, making them highly attractive candidates for tackling cancer. Further, γδ T cells can bridge innate and adaptive immunity to naturally discriminate cancers from healthy tissues and support wound healing. γδ T cell–based clinical trials, including off-the-shelf adoptive cell therapy and agonist antibodies, are yielding promising results in safety and efficacy. Founded on Adrian’s pioneering research into γδ T cells, our spin-out Gamma Delta Therapeutics has been harnessing γδ T cells to improve patient outcomes and survival rates throughout the past eight years.
| |
|
---|
|
|
|
|
Save the date for our next cancer prevention research conference |
| Our second annual cancer prevention research conference is taking place on 25 – 27 June in London next year. Hosted by us in partnership with the American Cancer Society, this global event will bring together leading researchers to discuss topics from discovery biology to population and implementation sciences. Be the first to know when registration opens – register your interest today to stay updated.
|
| |
|
|
|
| Together we are beating cancer |
| | |
---|
|
|
|
| You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here. Your details are safe with us. Check out our Privacy Policy. Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise. This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|